Hovione acquires ExtremoChem and its portfolio of proprietary sugars to support customers with stabilization and delivery of biopharmaceuticals
07.08.2025 - 18:05:50
Hovione has acquired ExtremoChem Lda, a start-up company with a portfolio of rare sugars, synthetic analogues of the natural molecules found in extremophiles.The acquisition provides Hovione with new high-performance functional materials, which have shown potential in stabilizing biopharmaceuticals.it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA-inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices.
Hovione's culture is based on innovation, quality, and dependability. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.
About ExtremoChem
ExtremoChem is a chemical synthesis start-up company focused on the development of organic synthetic sugars for the stabilization of biologicals under stress conditions.
For more information, please visit www.hovione.com or contact:
Will Frost | Global Communications Lead | wfrost@hovione.com |Tel: +351 915 388 177
View original content:
